US Navy sees the light

Article

The US Navy is proceeding with a programme allowing LASIK with IntraLase flap creation in naval aviators.

The US Navy is proceeding with a programme allowing LASIK with IntraLase flap creation in naval aviators. Until this point, PRK has been the preferred method of choice for refractive surgical correction.

Steven Schallhorn, MD of the Naval Medical Center in San Diego, US, speaking at the Hawaiian Eye 2007, discussed how the military has been reluctant to allow LASIK because contrast sensitivity took longer to be recovered postoperatively than after PRK. However, it was noted that there is a slow visual recovery period, of around three months, after PRK, whereas LASIK offers much faster recovery times.

Dr Schallhorn spoke of the technological advancements in LASIK. One large series study comparing conventional to wavefront-guided LASIK found that the addition of wavefront technology results in fewer higher-order corneal aberrations and therefore better postoperative vision. Another study found better quality of vision and faster visual recovery using the IntraLase femtosecond laser for flap creation compared with mechanical microkeratomes.

As a result of theses studies, the US Navy are prepared to begin a cautious programme allowing LASIK with IntraLase on naval aviators.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
© 2025 MJH Life Sciences

All rights reserved.